Twist Bioscience (NASDAQ:TWST) Upgraded by Leerink Partners to Outperform Rating

Twist Bioscience (NASDAQ:TWST) was upgraded by stock analysts at Leerink Partners from a “market perform” rating to an “outperform” rating in a report released on Tuesday, Marketbeat reports. The firm currently has a $70.00 target price on the stock. Leerink Partners’ price target would indicate a potential upside of 24.58% from the stock’s previous close.

TWST has been the subject of several other reports. Guggenheim boosted their price target on Twist Bioscience from $50.00 to $55.00 and gave the company a “buy” rating in a report on Monday, March 30th. Robert W. Baird set a $50.00 price target on Twist Bioscience in a report on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a report on Friday, March 27th. Evercore boosted their price target on Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday, February 3rd. Finally, TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a report on Thursday, January 8th. Eight analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $52.44.

Twist Bioscience Price Performance

TWST stock opened at $56.19 on Tuesday. Twist Bioscience has a 1 year low of $23.30 and a 1 year high of $66.06. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78. The stock’s 50 day moving average price is $50.46 and its 200 day moving average price is $41.06. The firm has a market cap of $3.45 billion, a P/E ratio of -43.90 and a beta of 2.22.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The business had revenue of $110.72 million during the quarter, compared to analyst estimates of $107.64 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company’s revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.66) earnings per share. On average, sell-side analysts expect that Twist Bioscience will post -1.86 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 8,061 shares of the company’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $65.29, for a total transaction of $526,302.69. Following the completion of the sale, the chief executive officer directly owned 858,887 shares in the company, valued at $56,076,732.23. This represents a 0.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Adam Laponis sold 4,000 shares of the company’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $60.00, for a total value of $240,000.00. Following the sale, the chief financial officer owned 118,694 shares of the company’s stock, valued at approximately $7,121,640. The trade was a 3.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 55,751 shares of company stock worth $2,917,695. 3.08% of the stock is currently owned by company insiders.

Institutional Trading of Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the company. Strs Ohio acquired a new stake in shares of Twist Bioscience during the 1st quarter worth $33,000. Quarry LP acquired a new stake in Twist Bioscience in the 3rd quarter valued at $28,000. Strategic Advocates LLC increased its holdings in Twist Bioscience by 562.7% in the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock valued at $34,000 after purchasing an additional 906 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after purchasing an additional 442 shares in the last quarter. Finally, Fifth Third Bancorp acquired a new stake in Twist Bioscience in the 1st quarter valued at $54,000.

More Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Revenue beat and solid top-line growth: Q2 revenue was $110.7M, up ~19% year-over-year and above consensus, supporting demand for Twist’s DNA‑synthesis products driven in part by AI-related customers. TWST Q2 revenue beat (Zacks)
• Positive Sentiment: Raised revenue outlook: Twist updated Q3 and FY‑2026 revenue guidance above Street expectations (Q3: ~$114–115M; FY: ~$442–447M), implying continued demand and helping the growth story. Press release with guidance (Business Wire)
• Positive Sentiment: Product expansion could broaden TAM: Launch of “Complex Genes” (early access) targets longer and more complex sequences, which may increase addressable demand from AI‑driven protein design and therapeutics customers. Complex Genes launch (Business Wire)
• Neutral Sentiment: Conference call and details available: Management provided prepared remarks and slides (transcript/slide deck available) — useful for assessing cadence of organic growth, customer mix and margin roadmap but not immediately decisive. Earnings call transcript (Seeking Alpha)
• Negative Sentiment: EPS missed and loss widened: Reported EPS was a loss (various reports show -$0.62 to -$0.71), missing consensus and reflecting a wider loss versus prior year, which pressured the stock despite the revenue beat. Loss widened (Benzinga)
• Negative Sentiment: Profitability remains weak: Negative net margin (~-19.6%) and negative ROE, with sell‑side models forecasting further FY losses — these metrics increase sensitivity to execution and make the stock vulnerable to near‑term multiple compression. Metrics and analyst context (MarketBeat)

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.